These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34431585)

  • 1. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance.
    Yamamoto N; Nakanishi Y; Gemma A; Nakagawa K; Sakamoto T; Akamatsu A; Ohe Y
    Cancer Sci; 2021 Nov; 112(11):4692-4701. PubMed ID: 34431585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan.
    Hiraizumi K; Honda C; Watanabe A; Nakao T; Midorikawa S; Abe H; Matsui N; Yamamoto T; Sakamoto T
    Int J Clin Oncol; 2024 Jul; 29(7):932-943. PubMed ID: 38844668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.
    Lim SM; Kim SW; Cho BC; Kang JH; Ahn MJ; Kim DW; Kim YC; Lee JS; Lee JS; Lee SY; Park KU; An HJ; Cho EK; Jang TW; Kim BS; Kim JH; Lee SS; Na II; Yoo SS; Lee KH
    Cancer Res Treat; 2020 Oct; 52(4):1112-1119. PubMed ID: 32599984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
    Nakagawa K; Kudoh S; Ohe Y; Johkoh T; Ando M; Yamazaki N; Seki A; Takemoto S; Fukuoka M
    J Thorac Oncol; 2012 Aug; 7(8):1296-303. PubMed ID: 22610257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.
    Kawasaki A; Hatake K; Matsumura I; Izutsu K; Hoshino T; Akamatsu A; Kakuuchi A; Tobinai K
    Int J Hematol; 2024 Jun; 119(6):667-676. PubMed ID: 38521840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
    Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
    Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
    Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance.
    Kiyohara Y; Uhara H; Ito Y; Matsumoto N; Tsuchida T; Yamazaki N
    J Dermatol; 2018 Apr; 45(4):408-415. PubMed ID: 29464755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.
    Uhara H; Tsuchida T; Kiyohara Y; Akamatsu A; Sakamoto T; Yamazaki N
    J Dermatol; 2022 Sep; 49(9):862-871. PubMed ID: 35607248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma.
    Yamazaki N; Kiyohara Y; Uhara H; Tsuchida T; Yoshida A; Yamada T; Komoto A
    J Dermatol; 2023 Sep; 50(9):1108-1120. PubMed ID: 37350027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
    Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.
    Uemura H; Shinohara N; Tomita Y; Nonomura N; Yamada T; Yoshida A; Komoto A
    Jpn J Clin Oncol; 2023 Jul; 53(8):730-737. PubMed ID: 37151051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer.
    Sabatier R; Nicolas E; Paciencia M; Jonville-Béra AP; Madroszyk A; Cecile M; Braticevic C; Duran S; Tassy L; Rouby F; Micallef J; Rousseau F
    J Geriatr Oncol; 2018 Sep; 9(5):494-500. PubMed ID: 29530494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
    Waterhouse D; Horn L; Reynolds C; Spigel D; Chandler J; Mekhail T; Mohamed M; Creelan B; Blankstein KB; Nikolinakos P; McCleod MJ; Li A; Oukessou A; Agrawal S; Aanur N
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):679-686. PubMed ID: 29442139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.